Radioactive hope: new drug targets Hard-to-Treat brain lymphoma
NCT ID NCT06132737
First seen May 14, 2026 · Last updated May 15, 2026 · Updated 1 time
Summary
This early-phase trial tests a radioactive drug called [90Y]Y-PentixaTher in 15 people with recurrent or refractory central nervous system (CNS) lymphoma. The drug is given once through a vein, and researchers will check safety, where the drug goes in the body, and whether it shrinks tumors. The goal is to find a safe dose and see if this approach can help control this difficult-to-treat cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CNS LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Hospital Essen
RECRUITINGEssen, Germany
Contact
-
University Hospital Rechts der Isar
RECRUITINGMunich, Bavaria, 81675, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.